N1-benzyl-N8-hydroxyoctanediamide | 149647-93-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N1-benzyl-N8-hydroxyoctanediamide
• 英文别名: octanedioic Acid Benzylamide Hydroxyamide；N-benzyl-N'-hydroxyoctanediamide
• CAS: 149647-93-8
• 化学式: C₁₅H₂₂N₂O₃
• 分子量: 278.351
• InChiKey: OWDYDLVCUCFVDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 8-(benzylamino)-8-oxooctanoate 在 羟胺 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 N1-benzyl-N8-hydroxyoctanediamide
  参考文献：
  名称：

  Precursor-Directed Biosynthesis of Aminofulvenes: New Chalanilines from Endophytic Fungus Chalara sp.

  摘要：

  植物内生真菌 Chalara sp. 能够将表观遗传修饰剂 vorinostat 生物转化为形成独特的含苯胺的聚酮类化合物，被命名为 chalanilines。在这里，我们试图通过改变前体 vorinostat 中的苯胺基团来扩展 chalaniline A 类分子的化学多样性。总共，通过两步合成制备了二十三种不同的 vorinostat 类似物，其中十九种被真菌转化为聚酮类化合物。选择产量最高的底物进行大规模前体导向生物合成，分离、纯化并结构表征了五种新化合物，包括两种氟代 chalanilines。结构阐明依赖于一维和二维核磁共振技术，并得到低分辨率和高分辨率质谱的支持。所有化合物均进行了生物活性测试，但在抗微生物或细胞存活率测定中均不活跃。含氨基富烯的天然产物很少见，而这种高产率的前体导向过程允许对这类化合物进行多样化。

  DOI：

  10.3390/molecules26154418

文献信息

• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
  申请人：Sloan-Kettering Institute for Cancer Research

  公开号：US06511990B1

  公开（公告）日：2003-01-28

  The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

  本发明提供了具有以下结构的化合物：其中R1和R2中的每一个都是取代或未取代的芳基、环烷基、环烷基氨基、萘基、吡啶氨基、哌啶基、叔丁基、芳氧基、芳基氧基或吡啶基；其中A是酰胺基团、—O—、—S—、—NH—或—CH2—；n是从3到8的整数。本发明还提供了一种选择性诱导肿瘤细胞生长停滞、终末分化和/或凋亡的方法，从而抑制这些细胞的增殖。此外，本发明提供了一种治疗患有以肿瘤细胞增殖为特征的肿瘤的患者的方法。最后，本发明提供了一种包括药用可接受载体和上述化合物的治疗上可接受剂量的药物组合物。
• Methods of treating cancer with HDAC inhibitors
  申请人：——

  公开号：US20040127523A1

  公开（公告）日：2004-07-01

  The present invention relates to methods of treating cancers, e.g., lymphoma. More specifically, the present invention relates to methods of treating diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

  本发明涉及治疗癌症的方法，例如淋巴瘤。更具体地说，本发明涉及通过给予含有HDAC抑制剂的药物组合物，例如suberoylanilide羟肟酸（SAHA），治疗弥漫性大B细胞淋巴瘤（DLBCL）的方法。这些药物组合物的口服制剂具有良好的药代动力学特性，例如高生物利用度，并且令人惊讶地在延长的时间内产生高水平的活性化合物血浓度。本发明还提供了这些药物组合物的安全、每日剂量方案，易于遵循，并在体内产生治疗有效量的HDAC抑制剂。
• Polymorphs of suberoylanilide hydroxamic acid
  申请人：Miller Thomas A.

  公开号：US20080194692A1

  公开（公告）日：2008-08-14

  The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.

  本发明提供了通过给予含有强效HDAC抑制剂的药物组合物来选择性诱导肿瘤细胞的终端分化、细胞生长停滞和/或凋亡，并/或抑制组蛋白去乙酰化酶（HDAC）的方法。本发明中药物组合物中活性化合物的口服生物利用度出乎意料地高。此外，该药物组合物意外地产生了活性化合物的高、治疗有效的血液水平，持续时间较长。本发明还提供了一种安全的、每日剂量的服用方案，易于遵循，并在体内产生治疗有效量的HDAC抑制剂。本发明还提供了一种SAHA的Form I多晶形态，其具有独特的X射线衍射图案和差示扫描量热法（DSC）谱图，以及独特的晶体结构。
• Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
  申请人：Breslow Ronald

  公开号：US20070010536A1

  公开（公告）日：2007-01-11

  The present invention provides the compound having the formula: wherein each of R 1 and R 2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH 2 —; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

  本发明提供了具有以下式子的化合物：其中R1和R2分别为取代或未取代的芳基、环烷基、环烷基氨基、萘基、吡啶氨基、哌啶基、叔丁基、芳氧基、芳基烷氧基或吡啶基；其中A为酰胺基、-O-、-S-、-NH-或-CH2-；n为3到8的整数。本发明还提供了一种选择性诱导肿瘤细胞生长停滞、终末分化和/或凋亡的方法，从而抑制这些细胞的增殖。此外，本发明还提供了一种治疗具有肿瘤细胞增殖特征的患者的方法。最后，本发明提供了一种包括药学上可接受的载体和上述化合物的治疗上可接受的剂量的药物组合物。